[1] Institute of Medicine (US). Clinical practice guidelines we can trust. Washington, DC: The National Academies Press, 2011. ISBN: 9780309216463.
[2] 中华医学会感染病学分会, GRADE 中国中心. 中国乙型肝炎病毒母婴传播防治指南(2019 年版). 中华传染病杂志, 2019, 37: 388-396.
[3] World Health Organization. WHO handbook for guideline development2nd edition. Geneva: WHO Press, 2014. ISBN: 978 9241548960.
[4] Atkins D, Best D, Briss PA., et al. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328: 1490.
[5] US Preventive Services Task Force; Owens DK, Davidson KW, et al. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA, 2019, 322: 857-867.
[6] Nelson HD, Fu R, Zakher B, et al. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 2019, 322: 868-886.
[7] Prasad K, Siemieniuk R, Hao Q, et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. BMJ, 2018, 363:k5130.
[8] Hao Q, Tampi M, O'Donnell M, et al. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. BMJ, 2018, 363: k5108.
[9] Stergiou GS, Palatini P, Asmar R, et al. Recommendations and Practical Guidance for performing and reporting validation studies according to the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO). J Hypertens, 2019, 37: 459-466.
[10] Boubouchairopoulou N, Kollias A, Atkins N, et al. Validation of blood pressure monitors using the aami and iso protocols: an overview of their recent application. Journal of Hypertension, 2016, 34: E286.
[11] Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommen-dations for potential adverse events. Respiration, 2019, 97: 173-184.
[12] Noth I, Wijsenbeek M, Kolb M, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the tomorrow and inpulsis trials. American Journal of Respiratory and Critical Care Medicine, 2017, 195: A5383.
[13] 中华预防医学会, 中国疾病预防控制中心免疫规划中心. 中国成人乙型肝炎免疫预防技术指南. 中国病毒病杂志, 2012, 2: 11-16.
[14] 中华医学会妇产科学分会绝经学组. 绝经管理与绝经激素治疗中国指南(2018). 中华妇产科杂志, 2018, 53: 729-739.
[15] Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med, 2018, 378: 911-923.
[16] Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med, 2016, 374: 2324-2334.
[17] 田雅婷. 我国95% 诊断标准外国制定现状需改变. 光明日报, 2016-12-20.
[18] 陈耀龙, 王辰. 临床实践指南寻觅“中国道路”. 健康报, 2018-02-26. |
